T7276

SD 0006 (SD-06) is a MAPK p38 alpha inhibitor with an IC50 of 110 nM, indicated for the treatment of arthritis.

Keap1-Nrf2-IN-6 is a potent, selective inhibitor of the Keap1-Nrf2 protein−protein interaction (PPI), demonstrating an inhibitory concentration (IC50) of 41 nM and a dissociation constant (Kd) of 68 nM.

Proteasome-IN-4, a non-covalent proteasome inhibitor (IC 50 = 8.39 nM), exhibits potent antiproliferative effects on RPMI-8226, MM-1S, and MV-4-11 cell lines, making it valuable for cancer research.

AChE/BuChE-IN-1, a selective butyrylcholinesterase (BuChE) inhibitor derived from chrysin, exhibits a potent efficacy with an IC50 of 0.48 μM against BuChE and a lesser inhibitory effect on acetylcholinesterase (AChE) with an IC50 of 7.16 μM. It demonstrates significant hydroxyl radical (·OH) scavenging activity, achieving an IC50 of 0.1674 μM, and effectively inhibits reactive oxygen species (ROS) and Aβ 1-42 aggregation, including self-aggregation, copper (Cu 2+)-induced, and AChE-induced aggregation. Characterized by high blood-brain barrier (BBB) permeability, bioavailability, and low cellular toxicity, AChE/BuChE-IN-1 holds promising potential for Alzheimer's disease (AD) research.

EphA2 agonist 2 (Lead compound) is a selective agonist targeting the EphA2 receptor, with antitumor properties and the ability to cross the blood-brain barrier (BBB).

p53 Activator 3 is a potent activator of p53, demonstrating notable efficacy with an SC150 value of less than 0.05 mM. It effectively binds to mutant p53, reinstating its DNA-binding capability, and exhibits anti-tumor activity.